Joint Clinical Trials Office

You are here

A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia

Clinical Trial Details

This clinical trial is a Phase 1 study evaluating the safety of LAM-003 when administered to men and women with previously treated relapsed or refractory AML. Currently, there is a great unmet need for treating AML that has either not responded to or returned after other treatments. Based on laboratory and animal studies, it appears that LAM-003 may block some of the cell signals that cause AML to grow. 

Subjects will self-administer oral LAM-003 QD or BID continuously in repeated 28-day cycles. The amount of time each subject spends on study will vary significantly but on average time on study is expected to be approximately 4-6 months. 

Subjects will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects. Study participants will be compensated for their time. 

Key Eligibility: 
  • The study is open to men and women aged 18 years or older with a diagnosis of acute myeloid leukemia (AML). 
  • Subjects’ AML must have been previously treated and has progressed during or relapsed after prior therapy. 
  • Detailed eligibility will be reviewed by the study team. 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Tania J. Curcio, NP, FNP-BC
(212) 746-2571
tjc9003@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1710018692

ClinicalTrials.gov:

NCT03426605

Sponsor:

LAM-003-HEM-CLN02

Status

Open to Enrollment

Age Group

Adult

Sponsor